UPDATE: Jefferies Downgrades Esperion Therapeutics (ESPR) to Hold

February 12, 2021 7:30 AM EST
Get Alerts ESPR Hot Sheet
Price: $27.02 -0.07%

Rating Summary:
    9 Buy, 7 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - February 12, 2021 7:58 AM EST)

Jefferies analyst Michael Yee downgraded Esperion Therapeutics (NASDAQ: ESPR) from Buy to Hold with a price target of $30.00 (from $40.00).

The analyst commented, "We move to Hold bc: 1) Nexletol/ Nexlizet launch will take time as COVID dynamics and interactions in doc offices remain challenging, 2) there's wkly growth but not significant acceleration in script trends (hired new Chief Commercial Officer to try and resolve), 3)balance sheet has improved but investor uncertainty about cash remains, and 4) we are below cons on 2021-22. Stock not expensive at $975M cap ($1.3B EV) but it will take patience during 2021-22"

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $31.71 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

Jefferies & Co